Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study
CDK4/6 inhibitors with endocrine therapy are effective in elderly patients with metastatic HR+/HER2- breast cancer, though careful management is crucial to balance efficacy and minimize adverse events.
Authors
- Assunta Melaccio
- Felicia Maria Maselli
- Guido Giordano (ORCID: https://orcid.org/0000-0002-9310-1075)
- Gennaro Gadaleta‐Caldarola (ORCID: https://orcid.org/0000-0001-7120-8747)
- Antonio Pinto (ORCID: https://orcid.org/0000-0002-9425-9026)
- Antonio Cusmai (ORCID: https://orcid.org/0000-0002-2971-9495)
- Laura Lanotte (ORCID: https://orcid.org/0000-0002-9623-4869)
- Matteo Landriscina (ORCID: https://orcid.org/0000-0003-0591-9799)
- Chiara Guarini (ORCID: https://orcid.org/0000-0003-2225-6093)
- Antonella Licchetta
- Palma Fedele (ORCID: https://orcid.org/0000-0002-7437-4676)
- Maria Nicla Pappagallo
- Francesco Giotta (ORCID: https://orcid.org/0000-0001-5284-5281)
- Lucia Moraca
- Francesco Giuliani (ORCID: https://orcid.org/0000-0002-5707-2158)
- Vincenzo Emanuele Chiurì (ORCID: https://orcid.org/0000-0002-1314-6477)
- Antonio Gnoni
Institutions
- University of Foggia (IT)
- Ospedale San Paolo (IT)
- Istituto Tumori Bari (IT)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-10
- DOI
- https://doi.org/10.3390/cancers16203442
- Citations
- 6
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 2.51